Drug Approval | November 10, 2025
Glenmark secures China approval for Ryaltris
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
IOLCP has reported total income of Rs. 559.06 crores during the period ended June 30, 2025
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Subscribe To Our Newsletter & Stay Updated
